Hurdles in radiation planning for glioblastoma: Can delayed-contrast enhanced computed tomography be a potential solution?
delayed CECT
glioblastoma
radiation planning
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
06
07
2018
accepted:
02
11
2018
pubmed:
31
1
2019
medline:
4
12
2019
entrez:
31
1
2019
Statut:
ppublish
Résumé
Conformal radiation is the standard of care in treatment of glioblastoma. Although co-registration of magnetic resonance imaging (MRI) with early contrast enhanced computed tomography (CECT) is recommended for target delineation by consensus guidelines, ground realities in developing countries often result in availability of less-than-ideal MR sequences for treatment planning. Purpose of this study is to analyze the impact of incorporation of delayed-CECT sequences for radiation planning in glioblastomas, as an adjunct or alternative to MRI. Case records of all patients of glioblastoma treated at our center between 2011 and 2014 were retrospectively evaluated. Gross treatment volumes were delineated on T1 contrast MRI (m-GTV), early CECT (e-GTV) and delayed CECT (d-GTV); volumetric comparisons were made using repeated measures analysis of variance and pair-wise analysis. Although 96% of registered patients underwent postoperative MRI, only 38% of them had desirable sequences suitable for co-registration. Median duration between acquisition of postoperative MRI and surgery was 45 days (range, 33-60), whereas that between MRI and treatment-planning CT was 5 days (range, 1-10). Statistically significant differences (P < 0.0001) were obtained between mean volumes of e-GTV (41.20cc), d-GTV (58.09cc) and m-GTV (60.52cc). Although the mean GTV increased by 46% between early CECT and MRI, the difference was only 4% between delayed CECT and MRI. Delayed CECT is superior to early CECT for co-registration with MRI for target delineation, especially when available MR sequences are less-than-ideal for treatment planning, and can be considered as the most appropriate adjunct as well as an alternative to MRI, compared to early CECT.
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e103-e108Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.
Références
Nabors LB, Portnow J, Ammirati M, et al. NCCN guidelines insights: central nervous system cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:1331-1345.
Stupp R, Brada M, Van Den Bent MJ, Tonn JC, Pentheroudakis G. High-grade glioma: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl_3):iii93-iii101.
Cabrera AR, Kirkpatrick JP, Fiveash JB, et al. Radiation therapy for glioblastoma: executive summary of an American society for radiation oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2016;6:217-225.
Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. Validation of CT-MRI fusion for intraoperative assessment of stereotactic accuracy in DBS surgery. Mov Disord. 2014;29:1788-1795.
Kooy HM, Van Herk M, Barnes PD, et al. Image fusion for stereotactic radiotherapy and radiosurgery treatment planning. Int J Radiat Oncol Biol Phys. 1994;28:1229-1234.
Daisne JF, Sibomana M, Bol A, Cosnard G, Lonneux M, Grégoire V. Evaluation of a multimodality image (CT, MRI and PET) coregistration procedure on phantom and head and neck cancer patients: accuracy, reproducibility and consistency. Radiother Oncol. 2003;69:237-245.
Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27:525-551.
Hayman LA, Evans RA, Bastion FO, Hinck VC. Delayed high dose contrast CT: identifying patients at risk of massive hemorrhagic infarction. Am J Roentgenol. 1981;136:1151-1159.
Davis JM, Davis KR, Newhouse J, Pfister RC. Expanded high iodine dose in computed cranial tomography: a preliminary report. Radiology. 1979;131:373-380.
Chang EL, Akyurek S, Avalos T, et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys. 2007;68:144-150.
Dice LR. Measures of the amount of ecologic association between species. Ecology. 1945;26:297-302.
Zijdenbos AP, Dawant BM, Margolin RA, Palmer AC. Morphometric analysis of white matter lesions in MR images: method and validation. IEEE Trans Med Imaging. 1994;13:716-724.
Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978;49:333-343.
Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71:1-9.
Burger PC, Dubois PJ, Schold Jr SC, et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg. 1983;58:159-169.
Heesters MA, Wijrdeman HK, Struikmans H, Witkamp T, Moerland MA. Brain tumor delineation based on CT and MR imaging. Implications for radiotherapy treatment planning. Strahlenther Onkol. 1993;169:729-733.
Salem A, Hashem SA, Al-Rashdan A, et al. The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care. Hematol Oncol Stem Cell Ther. 2011;4:116-120.
Ray S, Bonafede MM, Mohile NA. Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. American health & drug benefits. 2014;7:140.
Irwin C, Hunn M, Purdie G, Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol. 2007;85:339-343.
Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol. 2000;57:131-136.
Datta NR, Samiei M, Bodis S. Radiation therapy infrastructure and human resources in low-and middle-income countries: present status and projections for 2020. Int J Radiat Oncol Biol Phys. 2014;89:448-457.
Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas: a simple and reproducible method. Cancer. 1988;62:2152-2165.
Rong Y, Durden DL, Van Meir EG, Brat DJ. ‘Pseudopalisading'necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol. 2006;65:529-539.
Shalen PR, Hayman LA, Wallace S, Handel SF. Protocol for delayed contrast enhancement in computed tomography of cerebral neoplasia. Radiology. 1981;139:397-402.
Wesbey G. Artifacts in MRI: description, causes, and solutions. Clinical magnetic resonance imaging. 1996:88-144.
Ten Haken RK, Thornton Jr AF, Sandler HM, et al. A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiother Oncol. 1992;25:121-133.
Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner SF, Leach MO. Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol. 1997;42:1-5.
Zou KH, Warfield SK, Bharatha A, et al. Statistical validation of image segmentation quality based on a spatial overlap index1: scientific reports. Acad Radiol. 2004;11:178-189.